Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: -

Seligson & Co Global Top 25 Pharmac.

+ Add to Watchlist

SEL25PB:FH

14.61 EUR 0.000.00%

As of 01:59:30 ET on 01/29/2015.

Snapshot for Seligson & Co Global Top 25 Pharmac. (SEL25PB)

Year To Date: +11.29% 3-Month: +17.91% 3-Year: +25.06% 52-Week Range: 10.01 - 14.74
1-Month: +11.02% 1-Year: +40.20% 5-Year: +20.22% Beta vs HEXP: 0.61

Mutual Fund Chart for SEL25PB

No chart data available.
  • SEL25PB:FH 14.61
  • 1M
  • 1Y
Interactive SEL25PB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for SEL25PB

Seligson & Co Global Top 25 Pharmaceuticals is an open-end fund incorporated in Finland. The Fund's objective is a return that follows the return of the world's top 25 pharmaceutical companies. The Fund invests in a basket of equities of the world's top 25 pharmaceutical companies.

Inception Date: 01-15-2000 Telephone: 358-9-6817-8200
Managers: JANI HOLMBERG / JAANA TIMONEN
Web Site: www.seligson.fi/

Fundamentals for SEL25PB

NAV (on 2015-01-29) 14.61
Assets (M) (on 2014-12-31) 182.38
Fund Leveraged N
Minimum Investment 1.00
Minimum Subsequent Investment 1.00

Dividends for SEL25PB

Dividend Type Omitted
Dividend Frequency Annual
Last Dividend Net -
Dividend Yield (ttm) -

Fees & Expenses for SEL25PB

Front Load 0.00
Back Load 0.50
Current Mgmt Fee 0.50
Redemption Fee 0.50
12b1 Fee -
Expense Ratio 0.61

Top Fund Holdings for SEL25PB

Filing Date: 12/31/2014
Name Position Value % of Total
Novartis AG 154,617 11,870,676 6.509%
Merck & Co Inc 247,654 11,746,958 6.441%
Johnson & Johnson 128,655 11,148,547 6.113%
Roche Holding AG 49,251 11,050,941 6.059%
Allergan Inc/United States 62,800 11,026,944 6.046%
Pfizer Inc 382,749 9,882,067 5.418%
Teva Pharmaceutical Industries 152,162 7,132,359 3.911%
Amgen Inc 53,953 7,130,550 3.910%
Celgene Corp 74,970 7,003,533 3.840%
AbbVie Inc 127,075 6,930,888 3.800%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil